KUALA LUMPUR: Duopharma Biotech Bhd
has recorded a net profit of RM60.59mil in the six months ended June 30, 2026, as compared to RM45.84mil in the year-ago period, underpinned by a more favourable product mix, the strengthening of the ringgit – which reduced input costs – and continued operational efficiencies.
The pharmaceutical group said in a results filing with Bursa Malaysia, its revenue for the period slipped slightly to RM482.24mil from RM484.52mil in the comparative period due to the normalisation of insulin sales to the public sector following the one-off surge recorded in the first half of financial year 2025 (1H25).
For the second quarter of the year, its net profit rose to RM29.87mil from RM20.2mil.
Quarterly revenue increased to RM234.36mil from RM221.78mil in the year-ago quarter. In line with its performance for the period, the board of directors declared an interim dividend of 1.5 sen per share with the entitlement date on Sept 4, 2026, and payment date on Sept 21.
Duopharma said its resilient financial performance in the 1H26, supported by its healthy order book, diversified revenue streams and established presence in the public healthcare sector, provides a solid foundation for the remainder of the financial year.
